HC Wainwright Has Lowered Expectations for Rockwell Medical (NASDAQ:RMTI) Stock Price

Rockwell Medical (NASDAQ:RMTI) had its price objective reduced by equities researchers at HC Wainwright from $7.00 to $3.00 in a report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 150.00% from the stock’s current price. HC Wainwright also issued estimates for Rockwell Medical’s Q1 2026 earnings at ($0.02) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.06) EPS.

Separately, StockNews.com lowered shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Friday, December 20th.

Rockwell Medical Stock Performance

Shares of NASDAQ:RMTI opened at $1.20 on Monday. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. Rockwell Medical has a 12 month low of $1.18 and a 12 month high of $5.15. The company has a market capitalization of $38.78 million, a price-to-earnings ratio of -24.00 and a beta of 1.55. The firm’s 50-day moving average is $1.82 and its 200 day moving average is $2.58.

Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Thursday, March 20th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). Rockwell Medical had a negative net margin of 1.25% and a positive return on equity of 8.55%. The business had revenue of $24.67 million for the quarter, compared to the consensus estimate of $23.65 million. Research analysts predict that Rockwell Medical will post 0.03 EPS for the current year.

Institutional Trading of Rockwell Medical

A number of large investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in Rockwell Medical by 285.8% during the 4th quarter. Renaissance Technologies LLC now owns 442,350 shares of the company’s stock valued at $902,000 after purchasing an additional 327,678 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Rockwell Medical in the third quarter valued at about $534,000. Walleye Capital LLC purchased a new stake in Rockwell Medical in the third quarter worth about $435,000. Marshall Wace LLP grew its holdings in Rockwell Medical by 17.2% during the 4th quarter. Marshall Wace LLP now owns 596,359 shares of the company’s stock worth $1,217,000 after acquiring an additional 87,685 shares in the last quarter. Finally, Corsair Capital Management L.P. bought a new position in Rockwell Medical during the 3rd quarter worth about $298,000. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.